Unknown

Dataset Information

0

Biophysical model to predict lung delivery from a dual bronchodilator dry-powder inhaler.


ABSTRACT: A biophysical lung model was designed to predict inhaled drug deposition in patients with obstructive airway disease, and quantitatively investigate sources of deposition variability. Different mouth-throat anatomies at varying simulated inhalation flows were used to calculate the lung dose of indacaterol/glycopyrronium [IND/GLY] 110/50?µg (QVA149) from the dry-powder inhaler Breezhaler®. Sources of variability in lung dose were studied using computational fluid dynamics, supported by aerosol particle sizing measurements, particle image velocimetry and computed tomography. Anatomical differences in mouth-throat geometries were identified as a major source of inter-subject variability in lung deposition. Lung dose was similar across inhalation flows of 30-120?L/min with a slight drop in calculated delivery at high inspiratory flows. Delivery was relatively unaffected by inhaler inclination angle. The delivered lung dose of the fixed-dose combination IND/GLY matched well with corresponding monotherapy doses. This biophysical model indicates low extra-thoracic drug loss and consistent lung delivery of IND/GLY, independent of inhalation flows. This is an important finding for patients across various ages and lung disease severities. The model provides a quantitative, mechanistic simulation of inhaled therapies that could provide a test system for estimating drug delivery to the lung and complement traditional clinical studies.

SUBMITTER: Dolovich MB 

PROVIDER: S-EPMC6733285 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Biophysical model to predict lung delivery from a dual bronchodilator dry-powder inhaler.

Dolovich Myrna B MB   Kuttler Andreas A   Dimke Thomas J TJ   Usmani Omar S OS  

International journal of pharmaceutics: X 20190530


A biophysical lung model was designed to predict inhaled drug deposition in patients with obstructive airway disease, and quantitatively investigate sources of deposition variability. Different mouth-throat anatomies at varying simulated inhalation flows were used to calculate the lung dose of indacaterol/glycopyrronium [IND/GLY] 110/50 µg (QVA149) from the dry-powder inhaler Breezhaler<sup>®</sup>. Sources of variability in lung dose were studied using computational fluid dynamics, supported by  ...[more]

Similar Datasets

| S-EPMC8043385 | biostudies-literature
| S-EPMC4444630 | biostudies-other
| S-EPMC9227944 | biostudies-literature
| S-EPMC8060712 | biostudies-literature
| S-EPMC5553717 | biostudies-literature
| S-EPMC6599298 | biostudies-literature
| S-EPMC10686290 | biostudies-literature
| S-EPMC4047113 | biostudies-other
| S-EPMC9237582 | biostudies-literature
| S-EPMC4267517 | biostudies-literature